AQUESTIVE THERAPEUTICS INC (AQST) Fundamental Analysis & Valuation

NASDAQ:AQST • US03843E1047

4.22 USD
-0.04 (-0.94%)
At close: Mar 6, 2026
4.1639 USD
-0.06 (-1.33%)
After Hours: 3/6/2026, 8:01:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AQST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, AQST scores 2 out of 10 in our fundamental rating. AQST was compared to 193 industry peers in the Pharmaceuticals industry. AQST has a bad profitability rating. Also its financial health evaluation is rather negative. AQST has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. AQST Profitability Analysis

1.1 Basic Checks

  • AQST had negative earnings in the past year.
  • AQST had a negative operating cash flow in the past year.
  • AQST had negative earnings in each of the past 5 years.
  • In the past 5 years AQST always reported negative operating cash flow.
AQST Yearly Net Income VS EBIT VS OCF VS FCFAQST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • The Return On Assets of AQST (-42.14%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -42.14%
ROE N/A
ROIC N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AQST Yearly ROA, ROE, ROICAQST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

  • AQST's Gross Margin of 60.28% is fine compared to the rest of the industry. AQST outperforms 69.95% of its industry peers.
  • In the last couple of years the Gross Margin of AQST has grown nicely.
  • AQST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
AQST Yearly Profit, Operating, Gross MarginsAQST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. AQST Health Analysis

2.1 Basic Checks

  • AQST does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for AQST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AQST Yearly Shares OutstandingAQST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AQST Yearly Total Debt VS Total AssetsAQST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • AQST has an Altman-Z score of -1.64. This is a bad value and indicates that AQST is not financially healthy and even has some risk of bankruptcy.
  • AQST's Altman-Z score of -1.64 is in line compared to the rest of the industry. AQST outperforms 46.11% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.64
ROIC/WACCN/A
WACC9.3%
AQST Yearly LT Debt VS Equity VS FCFAQST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

  • AQST has a Current Ratio of 5.93. This indicates that AQST is financially healthy and has no problem in meeting its short term obligations.
  • AQST's Current ratio of 5.93 is fine compared to the rest of the industry. AQST outperforms 67.88% of its industry peers.
  • A Quick Ratio of 5.62 indicates that AQST has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 5.62, AQST is doing good in the industry, outperforming 66.32% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.93
Quick Ratio 5.62
AQST Yearly Current Assets VS Current LiabilitesAQST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. AQST Growth Analysis

3.1 Past

  • AQST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.98%

3.2 Future

  • Based on estimates for the next years, AQST will show a very strong growth in Earnings Per Share. The EPS will grow by 22.81% on average per year.
  • The Revenue is expected to grow by 42.01% on average over the next years. This is a very strong growth
EPS Next Y24.9%
EPS Next 2Y21.17%
EPS Next 3Y25.44%
EPS Next 5Y22.81%
Revenue Next Year11.33%
Revenue Next 2Y32.78%
Revenue Next 3Y56.64%
Revenue Next 5Y42.01%

3.3 Evolution

AQST Yearly Revenue VS EstimatesAQST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
AQST Yearly EPS VS EstimatesAQST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. AQST Valuation Analysis

4.1 Price/Earnings Ratio

  • AQST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AQST. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQST Price Earnings VS Forward Price EarningsAQST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQST Per share dataAQST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as AQST's earnings are expected to grow with 25.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.17%
EPS Next 3Y25.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AQST Dividend Analysis

5.1 Amount

  • AQST does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AQST Fundamentals: All Metrics, Ratios and Statistics

AQUESTIVE THERAPEUTICS INC

NASDAQ:AQST (3/6/2026, 8:01:00 PM)

After market: 4.1639 -0.06 (-1.33%)

4.22

-0.04 (-0.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-04
Earnings (Next)05-11
Inst Owners61.45%
Inst Owner Change18.63%
Ins Owners3.7%
Ins Owner Change-1.19%
Market Cap514.84M
Revenue(TTM)N/A
Net Income(TTM)-68.92M
Analysts84
Price Target9.41 (122.99%)
Short Float %17.69%
Short Ratio3.72
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.44%
Min EPS beat(2)-3.59%
Max EPS beat(2)18.46%
EPS beat(4)1
Avg EPS beat(4)-15.2%
Min EPS beat(4)-38.41%
Max EPS beat(4)18.46%
EPS beat(8)2
Avg EPS beat(8)-15.3%
EPS beat(12)6
Avg EPS beat(12)0.72%
EPS beat(16)10
Avg EPS beat(16)5.11%
Revenue beat(2)0
Avg Revenue beat(2)-8.18%
Min Revenue beat(2)-13.36%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-16.45%
Min Revenue beat(4)-30.1%
Max Revenue beat(4)-2.99%
Revenue beat(8)2
Avg Revenue beat(8)-1.61%
Revenue beat(12)5
Avg Revenue beat(12)1.04%
Revenue beat(16)9
Avg Revenue beat(16)4.52%
PT rev (1m)2.47%
PT rev (3m)-10.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.62%
EPS NY rev (1m)-0.53%
EPS NY rev (3m)-0.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.86
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.78
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.36
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.28%
FCFM N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
F-Score1
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.5%
Cap/Sales 1.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.93
Quick Ratio 5.62
Altman-Z -1.64
F-Score1
WACC9.3%
ROIC/WACCN/A
Cap/Depr(3y)67.19%
Cap/Depr(5y)49.48%
Cap/Sales(3y)2.51%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-36.84%
EPS Next Y24.9%
EPS Next 2Y21.17%
EPS Next 3Y25.44%
EPS Next 5Y22.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.98%
Revenue Next Year11.33%
Revenue Next 2Y32.78%
Revenue Next 3Y56.64%
Revenue Next 5Y42.01%
EBIT growth 1Y-166.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.51%
EBIT Next 3Y-18.72%
EBIT Next 5Y29.88%
FCF growth 1Y-956.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-827%
OCF growth 3YN/A
OCF growth 5YN/A

AQUESTIVE THERAPEUTICS INC / AQST FAQ

What is the fundamental rating for AQST stock?

ChartMill assigns a fundamental rating of 2 / 10 to AQST.


What is the valuation status for AQST stock?

ChartMill assigns a valuation rating of 1 / 10 to AQUESTIVE THERAPEUTICS INC (AQST). This can be considered as Overvalued.


How profitable is AQUESTIVE THERAPEUTICS INC (AQST) stock?

AQUESTIVE THERAPEUTICS INC (AQST) has a profitability rating of 1 / 10.


How financially healthy is AQUESTIVE THERAPEUTICS INC?

The financial health rating of AQUESTIVE THERAPEUTICS INC (AQST) is 3 / 10.